Peptide ligands can bind to distinct sites in integrin alphaIIbbeta3 and elicit different functional responses.
The spatial relationship between the binding sites for two cyclic peptides, cyclo(S,S)KYGCRGDWPC (cRGD) and cyclo(S,S)KYGCHarGDWPC (cHarGD), high affinity analogs for the RGD and HLGGAKQAGDV peptide ligands, in integrin alphaIIbbeta3 (GPIIb-IIIa) has been characterized. For this purpose, cRGD and cHarGD were labeled with fluorescein isothiocyanate and tetramethylrhodamine 5-isothiocyanate, respectively. Both cyclic peptides were potent inhibitors of fibrinogen binding to alphaIIbbeta3, particularly in the presence of Mn2+; IC50 values for cRGD and cHarGD were 1 and <0.1 nM in the presence of Mn2+. Direct binding experiments and fluorescence resonance energy transfer analysis using the purified receptor showed that both peptides interacted simultaneously with distinct sites in alphaIIbbeta3. The distance between these sites was estimated to be 6.1 +/- 0.5 nm. Although cRGD bound preferentially to one site and cHarGD to the other, the sites were not fully specific, and each cyclic peptide or its linear counterpart could displace the other to some extent. The binding affinity of the cHarGD site was dramatically affected by Mn2+. cRGD, but not cHarGD, bound to recombinant beta3-(95-373) in a cation-dependent manner, indicating that the cRGD site is located entirely within this fragment. With intact platelets, binding of c-RGD and cHarGD to alphaIIbbeta3 resulted in distinct conformational alterations in the receptor as indicated by the differential exposure of ligand-induced binding site epitopes and also induced the opposite on membrane fluidity as shown by electron paramagnetic resonance analyses using 5-doxylstearic acid as a spin probe. These data support the concept the two peptide ligands bind to distinct sites in alphaIIbbeta3 and initiate different functional consequences within the receptor itself and within platelets.
Cierniewski
C S
CS
Department of Biophysics, Medical University in Lodz, 90-131 Lodz, Poland.
Byzova
T
T
Papierak
M
M
Haas
T A
TA
Niewiarowska
J
J
Zhang
L
L
Cieslak
M
M
Plow
E F
EF
D001665:Binding Sites; D002118:Calcium / Q000494:pharmacology; D002413:Cations, Divalent / Q000494:pharmacology; D004735:Energy Transfer; D000939:Epitopes; D019793:Fluorescein; D008024:Ligands; D008345:Manganese / Q000494:pharmacology; D018716:Molecular Mimicry; D009842:Oligopeptides; D010456:Peptides, Cyclic / Q000378:metabolism*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000378:metabolism*; D011485:Protein Binding; D019030:Receptors, Vitronectin / Q000378:metabolism
D002413:Cations, Divalent; D000939:Epitopes; D008024:Ligands; D009842:Oligopeptides; D010456:Peptides, Cyclic; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D019030:Receptors, Vitronectin; C119707:cyclo(S,S)KYGCRGDWPC; C098931:lysyl-tyrosyl-glycyl-cysteinyl-homoarginyl-glycyl-aspartyl-tryptophyl-prolyl-cysteine cyclic (4-10)-disulfide; D008345:Manganese; C047981:arginyl-glycyl-aspartic acid; D002118:Calcium; D019793:Fluorescein